Squalenoylation favorably modifies the in vivo pharmacokinetics and biodistribution of gemcitabine in mice

Drug Metabolism and Disposition

Volumn 36, Issue 8, 2008, Pages 1570-1577

  Reddy, L Harivardhan ^a   Khoury, Hania ^b   Paci, Angelo ^b   Deroussent, Alain ^b   Ferreira, Humberto ^a   Dubernet, Catherine ^a   Declèves, Xavier ^c   Besnard, Madeleine ^a   Chacun, Helène ^a   Lepêtre Mouelhi, Sinda ^a   Desmaële, Didier ^a   Rousseau, Bernard ^d   Laugier, Christelle ^d   Cintrat, Jean Christophe ^d   Vassal, Gilles ^b   Couvreur, Patrick ^a,e  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d SERVICE DE CHIMIE BIOORGANIQUE ET DE MARQUAGE   (France)

^e CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

1,1',2 TRISNORSQUALENIC ACID; 4 (N) TRISNORSQUALENOYLGEMCITABINE; DIFLUORODEOXYURIDINE; DRUG METABOLITE; FLOXURIDINE DERIVATIVE; GEMCITABINE; GEMCITABINE DERIVATIVE; SQUALENE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; COVALENT BOND; DRUG BLOOD LEVEL; DRUG DESIGN; DRUG DISTRIBUTION; DRUG INACTIVATION; DRUG METABOLISM; DRUG RELEASE; DRUG SQUALENOYLATION; DRUG URINE LEVEL; IN VIVO STUDY; ISOTOPE TRACING; KIDNEY METABOLISM; LEUKEMIA; LIVER; MEAN RESIDENCE TIME; MOUSE; NANOENGINEERING; NONHUMAN; PRIORITY JOURNAL; REPEATED DRUG DOSE; RETICULOENDOTHELIAL SYSTEM; SINGLE DRUG DOSE; SPLEEN; TISSUE DISTRIBUTION;

ANIMALS; ANTINEOPLASTIC AGENTS; CHROMATOGRAPHY, LIQUID; DEOXYCYTIDINE; FEMALE; MAGNETIC RESONANCE SPECTROSCOPY; MICE; MICE, INBRED DBA; SQUALENE; TANDEM MASS SPECTROMETRY; TISSUE DISTRIBUTION;

MURINAE; MUS;

EID: 47949098215     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.108.020735     Document Type: Article

References (20)

1. Abbruzzese JL, Grunewald R, Weeks EA, Gravel D, Adams T, Nowak B, Mineishi S, Tarassoff P, Satterlee W, Raber MN, et al. (1991) A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 9:491-498.
2. Bergman AM, Pinedo HM, Peters GJ (2002) Determinants of resistance to 2′,2′-difluorodeoxycytidine (gemcitabine). Drug Resist Updat 5:19-33.
3. Cappella P, Tomasoni D, Faretta M, Lupi M, Montalenti F, Viale F, Banzato F, D'Incalci M, and Ubezio P (2001) Cell cycle effects of gemcitabine. Int J Cancer 93:401-408.
4. Castelli F, Sarpietro MG, Ceruti M, Rocco F, and Cattel L (2006) Characterization of lipophilic gemcitabine prodrug-liposomal membrane interaction by differential scanning calorimetry. Mol Pharm 3:737-744.
5. Couvreur P, Reddy LH, Mangenot S, Poupaert JH, Desmaële D, Lepêtre-Mouelhi S, Pili B, Bourgaux C, Amenitsch H, and Ollivon M (2008) Discovery of new hexagonal supramolecular nanostructures formed by squalenoylation of an anticancer nucleoside analogue. Small 4:247-253.
6. Couvreur P, Stella B, Reddy LH, Hillaireau H, Dubernet C, Desmaële D, Lepêtre-Mouelhi S, Rocco F, Dereuddre-Bosquet N, Clayette P, et al. (2006) Squalenoyl nanomedicines as potential therapeutics. Nano Lett 6:2544-2548.
7. Fogli S, Danesi R, Gennari A, Donati S, Conte PF, and Del Tacca M (2002) Gemcitabine, epirubicin and paclitaxel: pharmacokinetic and pharmacodynamic interactions in advanced breast cancer. Ann Oncol 13:919-927.
8. Immordino ML, Brusa P, Rocco F, Arpicco S, Ceruti M, and Cattel L (2004) Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing lipophilic gemcitabine prodrugs. J Control Release 100:331-346.
9. Khoury H, Deroussent A, Reddy LH, Couvreur P, Vassal G, and Paci A (2007) Simultaneous determination of gemcitabine and gemcitabine-squalene by liquid chromatography-tandem mass spectrometry in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 858:71-78.
10. Kos J, Sekirnik A, Premzl A, Zavasnik-Bergant V, Langerholc T, Turk B, Werle B, Golouh R, Repnik U, Jeras M, et al. (2005) Carboxypeptidases cathepsins X and B display distinct protein profile in human cells and tissues. Exp Cell Res 306:103-113.
11. Moog R, Burger AM, Brandl M, Schüler J, Schubert R, Unger C, Fiebig HH, and Massing U (2002) Change in pharmacokinetic and pharmacodynamic behavior of gemcitabine in human tumor xenografts upon entrapment in vesicular phospholipid gels. Cancer Chemother Pharmacol 49:356-366.
12. Myhren F, Borretzen B, Dalen A, and Sandvold ML (2000), inventors; Clavis Pharma, assignee. Oral dosage forms of gemcitabine derivatives. European patent EP0986570. 2007 Nov 28.
13. Reddy LH, Dubernet C, Lepêtre-Mouelhi S, Desmaële D, and Couvreur P (2007) A new nanomedicine of gemcitabine displays enhanced anticancer activity in sensitive and resistant leukemia types. J Control Rel 124:20-27.
14. Reddy LH, Marque PE, Dubernet C, Lepêtre Mouelhi S, Desmaële D, and Couvreur P (2008) Preclinical toxicology (sub-acute and acute) and efficacy of a new squalenoyl gemcitabine anticancer nanomedicine. J Pharmacol Exp Ther 325:484-490.
15. Reid JM, Qu W, Safgren SL, Ames MM, Krailo MD, Seibel NL, Kuttesch J, and Holcenberg J (2004) Phase I trial and pharmacokinetics of gemcitabine in children with advanced solid tumors. J Clin Oncol 22:2445-2451.
16. Ruiz van Haperen VW, Veerman G, Eriksson S, Boven E, Stegmann AP, Hermsen M, Vermorken JB, Pinedo HM, and Peters GJ (1994) Development and molecular characterization of a 2′,2′-difluorodeoxycytidine-resistant variant of the human ovarian carcinoma cell line A2780. Cancer Res 54:4138-4143.
17. Strandberg TE, Tilvis RS, and Miettinen TA (1990) Metabolic variables of cholesterol during squalene feeding in humans: comparison with cholestyramine treatment. J Lipid Res 31:1637-1643.
18. Tilvis R, Kovanen PT, and Miettinen TA (1982) Metabolism of squalene in human fat cells. Demonstration of two-pool system. J Biol Chem 257:10300-10305.
19. Wang LR, Huang MZ, Xu N, Shentu JZ, Liu J, and Cai J (2005) Pharmacokinetics of gemcitabine in chinese patients with non-small-cell lung cancer. J Zhejiang Univ Sci B 6:446-450.
20. Xu Y, Keith B, and Grem JL (2004) Measurement of the anticancer agent gemcitabine and its deaminated metabolite at low concentrations in human plasma by liquid chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 802:263-270.